Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Reducing levels of low-density lipoprotein cholesterol (LDL-C) using statin therapy have resulted in reductions of 21% in CVD risk for every 1.03 mmol/l (40 mg/dl) decrease in LDL-C [1] . However, despite lowering LDL-C to 1.6-2.0 mmol/l (62-77 mg/dl), the residual risk of death and a CVD event in patients with established stable cardiovascular disease remains at 8.7% after 1 year [2] , and for those presenting with an acute coronary syndrome it remains at 22.4% after 2 years' treatment [3] , underscoring the need for novel treatment strategies capable of further reducing CVD risk. In this respect, epidemiological studies have identified low levels of high-density lipoprotein cholesterol (HDL-C) (<1.03 mmol/l or <40 mg/dl) to be an independent risk factor for CVD [4] [5] [6] [7] [8] [9] . One-third of patients with dyslipidemia in Europe have low levels of HDL-C and could benefit from HDL-C-raising therapy [10] . It has been suggested that elevating HDL-C by 0.03 mmol/l (1.0 mg/dl) may reduce CVD risk by 2-4% per year [7] . Conversely, high levels of HDL-C (>1.55 mmol/l or >60 mg/dl) are associated with reduced CVD risk [11] . The mechanism through which HDL-C confers its beneficial effects has been attributed in part to its ability to mediate reverse cholesterol transport (see Fig. 1 for an overview of this complex process), as well as its anti-inflammatory, antiapoptotic, antioxidative, and antithrombotic actions, the details of which are given in the following review articles [12] [13] [14] .
This article will review the treatment strategies for elevating HDL-C that are currently available and those that are still in clinical development. Raising HDL-C levels can be achieved by both lifestyle measures and drug treatment strategies. There is some clinical evidence suggesting that raising HDL-C using nicotinic acid [15, 16] or fibrates [17, 18] may modestly reduce future CVD risk. However, whether pharmacologically raising HDL-C actually reduces CVD risk independent of any effects on LDL-C, triglycerides, or other atherogenic factors, which are not routinely measured, remains to be demonstrated. In this regard, a recent meta-analysis of 108 randomized controlled clinical trials comprising nearly 300 000 patients has suggested that elevating HDL-C per se is not independently associated with any beneficial effect on CVD risk [19 ] .
Nonpharmacological strategies for highdensity lipoprotein raising
Certain lifestyle changes such as more exercise, reducing weight, moderate alcohol intake, and dietary changes may result in modest elevations in HDL-C levels [20] . Aerobic exercise has been reported to elevate HDL-C levels by 5-10%, with the increase related to the frequency and intensity of the exercise [21] , findings that may contribute in part to the reduced CVD risk and death obtained from physical activity [22, 23] . The actual mechanism through which exercise increases levels of HDL-C is unclear but has been attributed to elevated levels of lipoprotein lipase (see Fig. 1 ) [24] . Smoking reduces levels of HDL-C through an unknown mechanism, and its cessation has been reported to elevate HDL-C levels by 0.1 mmol/l (4 mg/dl) [25] , and, according to the Framingham study, smokers who gave up smoking had similar levels of HDL-C to nonsmokers [26] .
Obesity is associated with low levels of HDL-C and high levels of triglycerides as part of the metabolic syndrome. Studies suggest that a reduction in weight loss of 10 kg increased HDL-C levels by 20% [27] , with a meta-analysis suggesting a 0.007 mmol/l HDL-C increase for every 1 kg lost [28] . A 'low-fat' diet can lower both LDL-C and HDL-C [29] , whereas a high intake of n-3 polyunsaturated fats can elevate levels of HDL-C [30] . Diets high in omega-3 fatty acids or low in carbohydrates may also raise HDL-C levels. Finally, mild-to-moderate alcohol intake can elevate HDL-C levels by 0.23-0.33 mmol/l (9.0-13.1 mg/dl) [20] , but clearly any beneficial effects of alcohol will be lost if alcohol intake is not kept to within the The liver and intestine synthesize apoliprotein A-I (APOA-I), which combines with phospholipids (PLs) and free cholesterol (FC) secreted by the liver and the intestine, a process called lipidation, which is mediated by the ATP-binding cassette transporter 1 (ABCA1) pathway, forming nascent HDL-C. This nascent form of HDL-C then acquires more PL þ FC from peripheral tissues (such as skeletal muscle, adipose tissue, and skin) and lecithin : cholesterol acyltransferase (LCAT) and then generates cholesteryl ester (CE), forming mature HDL-C. More PL þ FC are acquired from triglyceride-rich lipoprotein through phospholipid transfer protein (PLTP) and lipoprotein lipase (LPL). The liver also synthesizes and secretes APOA-II, resulting in the formation of a subclass of HDL-C. CE and FC derived from mature HDL-C are directly and selectively taken up by the liver by the scavenger receptor class B type I (SR-BI). HDL-CE can also be transferred to APOB-containing lipoproteins (LDL/VLDL) by cholesteryl ester transfer protein (CETP) in exchange for triglyceride. The HDL-CE is then taken up by the liver through the LDL receptor (LDLR). In the liver, CE is hydrolyzed to FC, which is either excreted directly into bile or converted to bile acid (BA) before being excreted into the bile and feces.
guidelines. In addition, the beneficial effects of alcohol in this setting may be influenced by the age and sex of the patient.
Pharmacological strategies for elevating high-density lipoprotein cholesterol
The number of pharmacological agents that are currently available for specifically raising HDL-C is rather limited. These are reviewed in this section along with potential future pharmacological strategies for elevating HDL-C.
Nicotinic acid or niacin
Nicotinic acid (or Niacin) is the most effective pharmacotherapy currently available for raising HDL-C levels, increasing baseline HDL-C levels (15-35%), lowering LDL-C (16%) and reducing triglycerides (44%) [31, 32] . The mechanism through which nicotinic acid raises HDL-C levels has been attributed to three potential mechanisms (see Fig. 1 ): it reduces levels of nonesterified fatty acids and decreases hepatic triglyceride synthesis, resulting in lowering of very low density lipoprotein (VLDL) particles, which attenuates cholesteryl ester transfer protein (CETP)-mediated depletion of HDL-C (see Fig. 1 ) [33] ; it potentiates reverse cholesterol transport from macrophages through adenosine triphosphate cassette-binding (ABC) A1 transporter (ABCA1) [34] ; and it reduces uptake of HDL particles by the liver [35] .
Clinical studies have suggested that nicotinic acid can prevent the progression of atherosclerosis [36, 37] and improves CVD outcomes [15,16,38,39 ,40-42] (see Table 1 ), although whether these beneficial effects can be specifically attributed to improvements in HDL-C alone is unclear, given that this agent also has beneficial effects on LDL-C and triglycerides. The addition of extended release nicotinic acid (1000 mg, also called Niaspan) to existing statin therapy for 24 months has been reported to regress carotid atherosclerosis (as measured by carotid intima-media thickness), a surrogate endpoint that is predictive of CVD events [43] , when compared with existing statin therapy alone, in the 'Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol' ARBITER-2 [36] and ARBITER-3 [37] trials. Clinical studies have recently demonstrated that combination therapy with simvastatin and extended release nicotinic acid (Simcor 1000 mg/ 20 mg) is both well tolerated and efficacious in terms of modifying the atherogenic dyslipidemia profile [44, 45] . A clinical study investigating combination therapy with simvastatin and extended release nicotinic acid on CVD outcomes is currently ongoing and is estimated to complete in April 2011 (AIM-HIGH: Niacin Plus statin to Prevent Vascular Events; ClinicalTrials.gov Identifier: NCT00120289).
The main drawback to the clinical use of nicotinic acid is the adverse effect of flushing that occurs in about 80% of patients with the immediate release formulation, but is reduced to about 40% with extended release nicotinic acid, resulting in approximately 10% of patients discontinuing medication [46, 47] . The flushing is due to the generation of the vasodilatory prostaglandin D 2 through the DP1 receptor [48] , which results from the binding of nicotinic acid to its receptor [49] . The DP1 receptor antagonist, laropiprant (MK-0524), attenuates the nicotinic acid-induced flush [48] and has recently been combined with extended release nicotinic acid in a new formulation called Cordaptive (Tredaptive in the United States), resulting in about 50% less flushing [50, 51 ] . A large clinical study examining the effect of this novel drug combination on CVD outcomes is underway and is estimated to complete by Jan 2013 [the HPS-2 Treatment of HDL to Reduce the Incidence of Vascular Events (THRIVE) trial: ClinicalTrials.gov Identifier: NCT00461630].
Fibrates
Fibrates have been in clinical use for over the last 40 years, but recent clinical trials have predominantly focused on their beneficial effects of raising HDL-C (10-35%) and lowering triglycerides (20-50%), although they do also reduce LDL-C (5-20%) [52] . Fibrates are believed to raise HDL-C by stimulating hepatic apolipoprotein A-1 (APOA-I) and lipoprotein lipase activity (see Fig. 1 ) [53] and by acting as weak peroxisome proliferator-activated receptor (PPAR-a) agonists and activating specific genes encoding for APOA-I and APOA-II, lipoprotein lipase, SR-BI and ABCA1 (see Fig. 1 ) [52] . The effects of fibrates on CVD outcomes have been mixed, with some clinical studies reporting beneficial effects [17, 18, 54] and others not [40, 41] (see Table 1 ).
Peroxisome proliferator-activated receptor agonists
The PPAR agonists are transcription factors involved in lipid and glucose metabolism. PPAR-a agonists are primarily involved in lipid metabolism and are known to reduce triglycerides and modestly raise HDL-C levels by activating specific genes encoding for APOA-I and APOA-II, lipoprotein lipase, SR-BI and ABCA1 (see Fig. 1 ) [52] . More potent and specific PPAR-a agonists are being developed, such as LY518674, which has been demonstrated to raise HDL-C (2-16%) and reduce triglycerides (35-42%) following 12-week therapy in patients with atherogenic dyslipidemia [55] . Unfortunately, its use was associated with significant adverse and unwanted effects of worsening serum creatinine, increased LDL-C (20%) and elevated APOA-II levels (30%). CP-778 875, another PPAR-a agonist in development, which raised HDL-C (14%) and reduced triglycerides (26%), administered for 6 weeks in diabetic patients with atherogenic dyslipidemia, did not have any detrimental effects on serum creatinine, LDL-C or APOA-II levels [56] . Interestingly, both these PPAR-a agonists displayed a U-shaped dose effect on HDL-C levels, the explanation for which is unclear.
The insulin-sensitizing PPAR-g agonists, thiazolidinediones, are particularly useful in patients with diabetes and dyslipidemia, as they both elevate HDL-C and lower triglyceride levels. Pioglitazone and rosiglitazone have been reported to raise HDL-C by about 7-15% [57, 58] . Pioglitazone, in the recent PROACTIVE study, was demonstrated to reduce the secondary composite endpoint of all-cause mortality, nonfatal myocardial infarction (MI), and stroke in high-risk patients with diabetes, findings which were associated with a decrease in triglycerides (9.6%) and an elevation of HDL-C (8.9%) [59] . However, a recent meta-analysis of the PPAR-g agonist, rosiglitazone, suggests that its use may be associated with a 40% increased risk of MI, a detrimental effect which has been attributed to its potential LDL-C raising effect and its ability to precipitate congestive cardiac failure in predisposed individuals [60] .
The dual PPAR-a/PPAR-g agonists ('glitazars'), such as rasaglitazar [61] , muraglitazar [62] , and tesaglitazar [63] , have been reported to raise HDL-C by 30% in diabetic patients [61] , but have been hampered by concerns over safety issues (2.23 increased relative risk of CVD events and 7.40 increased relative risk of congestive cardiac failure) [62] and adverse effects (such as edema, weight increase, anemia, and leucopenia) [61, 63] .
Other drugs in clinical use which also raise high-density lipoprotein cholesterol
In general, the effect of statins on raising levels of HDL-C is modest (5-15%) [1] . Statins stimulate hepatic APOA-I, weakly inhibit CETP, and prevent the biosynthesis of hepatic cholesterol [64] . Bile acid sequestrants in high doses can lower LDL-C significantly, but they have a minor effect on HDL-C (by 5%) [65] . The cholesterolabsorption inhibitor ezetimibe has a small effect on HDL-C raising (by 5%), which can be potentiated by combining it with a statin or fibrate [65] .
Cholesteryl ester transfer protein inhibitors
Experimental animal and clinical studies have identified CETP inhibitors as a new class of agents that are capable of dramatically elevating plasma HDL-C levels [66] [67] [68] [69] [70] . CETP facilitates the transfer of cholesteryl esters from HDL-C to apolipoprotein B-containing lipoproteins such as LDL and VLDL (see Fig. 1 ), and, therefore, pharma-cologically inhibiting this process may be expected to elevate levels of HDL-C. The CETP inhibitor, torcetrapib, was withdrawn from clinical development in December 2006, following the findings that it was associated with an elevation in systolic blood pressure (2.8-6.6 mmHg) [42, [71] [72] [73] and increased risk of cardiovascular events (464 versus 373) and greater all-cause mortality (93 versus 59) in the 'Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events' (ILLUMINATE) trial [42] . Furthermore, despite reports that torcetrapib was able to elevate HDL-C levels by up to 72% and lower LDL-C by 25% [42, [71] [72] [73] , there was no benefit on carotid atherosclerosis progression (as measured by carotid intima-media thickness) in the 'Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor' (RADIANT1 and 2) trials, in which patients with either familial hypercholesterolemia [71] or mixed dyslipidemia [72] were treated for 2 years with torcetrapib and atorvastatin versus atorvastatin alone. Similarly, no beneficial effect was found with respect to coronary atherosclerosis progression in the 'Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation' (ILLUSTRATE) trial, following 2-year treatment with torcetrapib and atorvastatin versus atorvastatin alone in patients with established coronary artery disease [73] . The off-target toxic effects of torcetrapib have recently been attributed to a non-CETP-mediated effect of this drug on aldosterone release, the result of which was an elevation in systolic blood pressure, higher plasma sodium and bicarbonate levels and lower potassium levels [42, 74 ] , a finding that may have contributed to the worsened all-cause mortality observed in the ILLUMI-NATE study [42] and the failure to detect any beneficial effects in terms of carotid [71, 72] and coronary [73] atherosclerosis progression. A recent preclinical animal study has confirmed that treatment with torcetrapib resulted in an acute hypertensive response associated with an increase in plasma aldosterone and corticosterone in mice, rats, dogs, and rhesus monkeys, and was able to induce the release of aldosterone from adrenocortical cells [75 ] . A subsequent preclinical cell-based study has also demonstrated that torcetrapib treatment was able to induce the synthesis of both aldosterone and cortisol in human adrenal carcinoma cells in a manner that was dependent on intracellular calcium [76] . These recent data suggest that off-target toxic effects of torcetrapib unrelated to CETP inhibition may have been responsible for the observed adverse effects of this drug, meaning that CETP inhibition using another drug to raise HDL-C may not be associated with the same adverse effects.
In this regard, initial phase I clinical studies with variable treatment doses (10, 40, 150, and 300 mg) of another CEPT inhibitor, anacetrapib (MK-0859), for 2 weeks have been promising, reporting dramatic elevations in HDL-C (up to 129%) and significant reductions in LDL-C (up to 38%), with no significant effect on blood pressure [77] . Similar beneficial effects were found in a larger clinical study comprising 589 patients examining 8-week treatment with anacetrapib alone (10, 40, 150 , and 300 mg) or in combination with atorvastatin (20 mg), with no adverse effects on either blood pressure or blood levels of aldosterone, Na þ , K þ , or bicarbonate [78] . Furthermore, anacetrapib was not demonstrated to increase blood pressure or raise plasma aldosterone and corticosterone in animal studies [75 ] .
Another CETP inhibitor, dalcetrapib (RO4607381/JTT-705), which is also in clinical development, has been reported to elevate HDL-C (34%) and reduce LDL-C (7%) in a phase 2 clinical study comprising 189 mildly hyperlipidemic patients treated for 4 weeks with the drug administered alone at doses of 300, 600, or 900 mg [79] . Furthermore, this CETP inhibitor was found to be both well tolerated and efficacious when administered in conjunction with pravastatin 40 mg [80] , and unpublished safety and efficacy clinical studies have been completed with respect to combination therapy with atorvastatin 20 mg (ClinicalTrials.gov Identifier: NCT00689442) and simvastatin 40 mg (ClinicalTrials.gov Identifier: NCT00688558). Crucially, in preliminary animal studies, no off-target toxic effects in terms of blood pressure and aldosterone release have been observed with this particular CETP inhibitor [81] .
These initial studies are encouraging, as they suggest that anacetrapib and dalcetrapib may lack the off-target toxic effects observed with torcetrapib, at least in the short term. Clearly, larger clinical studies of longer duration are required to confirm the long-term safety profile and efficacy of these CETP inhibitors.
High-density lipoprotein cholesterol and APOA-I mimetics
In 1990, Badimon et al. [82] were the first to demonstrate that an infusion of HDL-C plasma fraction could regress atherosclerosis in cholesterol-fed rabbits. Since that study, a variety of HDL-C mimetics have been investigated in both experimental and animal models. APOA-I Milano is a genetic variant of APOA-I point mutation, with an arginine-to-cysteine substitution at position 173 present in individuals with a very low HDL-C level and no obvious signs of atherosclerosis [83] . Treatment with 5 weekly infusions of the recombinant form of APOA-I Milano (ET-216) has been reported to raise HDL-C levels and regress coronary atherosclerosis in 57 acute coronary syndrome patients [84] . Further larger clinical studies are required to confirm the efficacy of this treat-ment strategy and to determine whether it can impact on CVD outcomes.
Based on promising animal data and human studies demonstrating that the infusion of synthetic HDL containing APOA-I from human plasma could raise HDL-C levels and improve endothelial function (reviewed in [85 ] ), the effect of reconstituted HDL-C was investigated in 123 acute coronary syndrome patients in the 'Effect of rHDL on Atherosclerosis-Safety and Efficacy' (ERASE) trial [86] . However, following 4 weekly infusions of reconstituted HDL-C, no significant beneficial effects on coronary atheroma burden were observed, and, furthermore, abnormal liver function tests were noted at the higher doses [86] .
There are several APOA-I mimetic peptides in development, such as L-5F [87] and D-4F [88, 89] , which have been reported to mimic the beneficial effects of APOA-1, such as cholesterol efflux from macrophages, reduce inflammation, and halt atherosclerosis progression. Preliminary clinical data suggest that, in patients with established coronary artery disease, a single oral dose of D-4F is both safe and tolerable and may reduce the HDL inflammatory index [90 ] . Other peptides that are currently in development include L37pA [91, 92] and D37pA [92] , which have also been reported to protect myocardium against acute ischemia-reperfusion injury.
Phospholipids, which are components of HDL, may elevate HDL-C and target atherosclerosis. The oral administration of a synthetic phospholipid was reported to increase HDL-cholesterol and APOA-I levels and reduce aortic atherosclerosis progression in apoE-null mice [93] . A derivative of soy lecithin, phosphatidylinositol, administered daily over 2 weeks, was also found to elevate HDL-C and APOA-I levels in 16 normocholesterolemic volunteers [94] .
Novel pharmacological targets for raising high-density lipoprotein cholesterol
The elucidation of the biochemical pathways underlying HDL-C metabolism has identified several novel targets for raising HDL-C, some of which are reviewed in this section.
Liver X receptor agonists
In macrophages, ABCA1 mediates the removal of cholesterol from the periphery to lipid-poor APOA-I, and ABCG1, again in macrophages, transfers the cholesterol to mature HDL-C. Both macrophage ABCA1 and ABCG1 are under the transcriptional control of the nuclear liver X receptor (LXR), making the latter an important therapeutic target for increasing cholesterol efflux from macrophages (reviewed in [95] ). Synthetic agonists at the LXR receptor have been reported to promote macrophage cholesterol efflux, thereby halting or even regressing atherosclerosis progression in mice models in the absence of any significant effect on HDL-C [96] [97] [98] [99] . However, LXR agonists also promote hepatic lipogenesis and hypertriglyceridemia and raise LDL-C, which has hampered their clinical development. LXR agonists, which target the LXRb isoform, may exert an antiatherosclerotic effect without the observed hepatic side effects. In September 2007, following the completion of several phase I clinical trials in healthy volunteers, the LXR agonist, LXR-623, was withdrawn from further clinical development, although the reason for this is unclear.
Farnesoid X receptor modulators
The nuclear farnesoid X receptor (FXR) mediates a diverse variety of effects that include complex effects on lipid metabolism, including (reviewed in [95, 100] ): protecting the hepatocyte from the toxic effects of excess bile acids; reducing hepatic triglyceride synthesis and secretion as very low density lipoprotein; the downregulation of APOA-I and hepatic lipase, leading to reduced HDL-C levels; and elevated LDL-C levels. Therefore, FXR agonists such as GW4064 (cholic acid) have been reported to reduce serum triglycerides in db/db diabetic mice, whereas FXR antagonists have the potential to elevate HDL-C and reduce LDL-C levels.
Endothelial lipase modulators
Endothelial lipase, which is secreted from and binds to endothelial cells, hydrolyzes circulating HDL phospholipids, thereby decreasing HDL-C levels (reviewed in [101] ). The overexpression of endothelial lipase reduces HDL-C levels in animal studies [102, 103] , and, conversely, the genetic [103, 104] or antibody-mediated [105] inhibition of endothelial lipase has been demonstrated to augment HDL-C levels. Human studies suggest that plasma endothelial lipase levels are negatively associated with HDL-C levels [106] and are elevated in the presence of the metabolic syndrome [106] or inflammation [107] , and that loss-of-function mutations in the endothelial lipase gene are associated with raised HDL-C levels [108] . Therefore, a novel strategy for raising HDL-C levels would be to pharmacologically inhibit endothelial lipase activity.
Conclusion
Despite aggressive lowering of LDL-C, using statin therapy, patients still have a significant residual CVD risk. Low levels of HDL-C (<1.03 mmol/l or <40 mg/dl) are strongly and inversely related to CVD risk, such that raising HDL-C levels in patients with low HDL-C can enhance CVD risk reduction. However, large clinical studies are required to convincingly demonstrate that raising HDL-C per se actually improves CVD outcomes independent of any effects of LDL-C, triglycerides or other unaccounted-for atherogenic factors. Elevating HDL-C should be achieved in the first instance by nonpharmacological lifestyle measures such as changes in diet, reduction in alcohol intake, loss of weight, and exercising. There are pharmacological agents capable of raising HDL-C, which should be used in conjunction with effective LDL-C-lowering therapy. The currently available agents for elevating HDL-C include nicotinic acid, fibrates, and PPAR agonists, with emerging treatment strategies undergoing clinical testing, such as CETP inhibitors and HDL mimetics. Finally, ongoing research has identified novel targets for raising HDL-C levels, such as the nuclear receptors LXR and FXR and endothelial lipase, which may offer future treatment strategies for enhancing CVD risk reduction.
